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Abstract: It is well known that acute leukemia may accompany thromboembolic events; even 
severe thrombocytopenia does not prevent thrombosis. Coagulation dysfunction is the major 
pathophysiological background for thromboembolism in these patients. Most thromboembolism 
is localized in venous vessels in acute leukemic patients and it happens rarely in the artery. 
We report a case of acute thrombosis in the superior mesenteric artery as the ﬁ  rst symptom in 
a patient suffering from acute myeloid leukemia (FAB M4).
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Case report
A 56-year-old man suffered from a sudden onset of severe pain in upper abdomen 
together with vomiting for three hours. The pain was persistent without intermission. 
The patient was urgently admitted to our hospital on January 31, 2007. Abdominal 
CT revealed that there was a thromboembolism in superior mesenteric artery. The 
patient was healthy without any cardiovascular or metabolic disease previously, and 
had neither personal nor familial thromboembolic history. Body examination showed 
a normal status except weakened bowel sounds. Laboratory examinations showed that 
hemoglobin was 102 g/l, white blood cell (WBC), 5.77 × 109/l and platelet, 201 × 109/l. 
Lactate dehydrogenase (LDH) level increased (496 U/l). Prothrombin time (PT), active 
partial thromboplastin time (APTT), thrombin time (TT), and plasma ﬁ  brinogen level 
were at normal ranges. Emergent surgical embolectomy was performed successfully, 
which revealed a hard thrombus in the superior mesenteric artery. After surgery the 
patient received standard treatment of heparinization and AT-III substitution. On 
the third day post-operation, the patient had symptoms of high fever, fatigue, and 
weakness. Further blood examination showed that hemoglobin was only 78 g/l, 
WBC 20  × 109/l and platelets 78 × 109/l, and a few blast cells were identiﬁ  ed on the 
peripheral smear. A subsequent bone marrow examination conﬁ  rmed diagnosis of 
an acute myeloid leukemia (AML) FAB M4. Myeloblasts was 60%, monocytic cells 
was 22%, and there was no abnormal eosiniphilia. Chromosomal analyses showed a 
normal karyotype 46, XX without any abnormalities, and there was no translocation of 
t(15; 17)(q22; q21), t(11; 17)(q23; q21), inv(16)(p13; q22) or t(16; 16) (p13; q22) in 
blast cells. The polymerase chain reaction for the BCR/ABL, PML/RARa, AML1-ETO, 
or MLL rearrangement was negative. Immunophenotypical characterization of bone 
marrow cells by the ﬂ  ow-cytometry showed AML with expression of CD13, CD14, 
and CD33. A standard induction chemotherapy protocol (Idarubicin and cytarabine) 
did not get success of complete remission. The patient had complete remission 
after second chemotherapy (ﬂ  udarabine 50 mg/d × 5d, cytarabine 2.0 g/d × 6d and 
G-CSF 300 μg/d). After two courses of consolidation treatment: one was ﬂ  udarabine 
50 mg/d × 3d, cytarabine 1.0 g/d × 5d and G-CSF 300 μg/d, another was mitoxantroneInternational Journal of General Medicine 2008:1  8
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5 mg/d × 3d, cytarabine 0.1q12h × 7d and etoposide 0.1/d × 3d, 
the patient received an autoperipheral blood stem cell trans-
plantation. After transplantation the patient presented with 
heart failure and renal failure. The hematopoiesis in his bone 
marrow did not completely recover though there was no blast 
in it. He died eight months after transplantation because of 
heart failure and renal failure.
Discussion
Thromboembolism is a common complication in the patients 
suffering from acute leukemia, especially in the acute 
promyelocytic leukemia (APL) patients. It occurs mostly 
in the venous system. In a fellow-up observational cohort 
study of 379 adult acute leukemic patients, De Stefano and 
colleagues (2005) demonstrated that there were 6.3% of 
patients with thrombosis, 80% with venous thrombosis, and 
20% with arterial. And distribution of cases were: 1.4% in 
ALL, 9.6% in APL, and 3.2% in non-M3 AML patients (De 
Stefano et al 2005). The pathogenesis of thrombosis in acute 
leukemic patients is complicated. Traditional view is based 
on the Virchow’s triad, ie, slowed blood ﬂ  ow, impaired vessel 
integrity and alteration of blood components (Virchow 1998). 
New observations suggest that even more prothrombotic 
factors may potentiate the thromboembolic events in leukemic 
patients (Kwaan and Vicuna 2007): 1, Leukemic cells can 
produce several factors that may interfere coagulation 
and ﬁ  brinolytic systems, resulting in the hypercoagulable 
status in blood (Gale and Gordon 2001; Falanga 2005). 
2, Apoptosis of leukemic cells occurs spontaneously during 
rapid cell proliferation or under chemotherapy, resulting in 
an increased prothrombotic risk. 3, Coagulation inhibitors, 
such as antithrombin and protein C system, may be inhibited 
in acute leukemic patients, which reduces the anticoagula-
tion functions (Dixit et al 2006). 4, Certain inﬂ  ammatory 
cytokines, such as interleukin (IL)-1α, IL-6, tissue necrosis 
factor-beta (TNF-β) could be produced by either leukemic 
cells or normal host cells, which might stimulate TF expres-
sion on monocytes and could also downregulate anticoagu-
lant factors such as thrombomodulin, which may enhance 
procoagulant activities and further initiates the thrombosis 
(Rickles and Falanga 2001). Breccia and colleagues (2007) 
observed a close correlation between certain biological 
features of leukemic cells and the development of thrombotic 
events in APL patients. These characteristics included CD2 
and/or CD15 expression, bcr3 PML/RARa transcript type, 
FLT3-ITD, and elevated WBC (Breccia et al 2007).
The incidence of symptomatic thrombosis in the early 
stage of ALL patients is relatively low (1.4%), whereas it 
is signiﬁ  cantly increased during the further chemotherapy, 
which may be up to 10.6% (De Stefano et al 2005). 
L-asparaginase is an essential drug for ALL but its major 
complication is thrombosis. It might impair the balance of 
hemostatic system by reducing the synthesis of both coagula-
tion factors and inhibitors. It is demonstrated that coagulation 
inhibitors, ie, antithrombin, protein C and proteins S were 
signiﬁ  cantly reduced during asparaginase therapy (Ruud 
et al 2006). Thrombosis in central nervous system is a 
asparaginase-related thrombosis, which occurs in 1%–3% 
of patients (Payne and Vora 2007). Most of the thrombotic 
events occurred during the induction phase of therapy. Lower 
doses of asparaginase with a long period may associate with 
the highest incidence of thrombosis in ALL patients (Caruso 
et al 2006).
Although acute leukemic patients have high risk of throm-
boembolism, the preventive treatment of this complication 
is still controversial due to the higher risk of hemorrhage in 
the patients. Up to now, there is no recommended guideline 
of anticoagulant therapy in the acute leukemia patients 
except APL patients with high leukocyte counts or at high 
risk of developing ATRA syndrome (Chong and Lee 2007). 
Unfractionated heparin (UFH) and low molecular weight 
heparin (LMWH) are efﬁ  cacious for the thromboembo-
lism prophylaxis and treatment in acute leukemia patients. 
When the platelet count decreased below 50 × 109/l the risk 
of bleeding may signiﬁ  cantly increased with anticoagulant 
prophylaxis (Tapson et al 2007).
Conclusion
The present case report indicates that an unexpected thrombo-
embolic event in a healthy patient might also be the symptom 
of an underlying hematological disorder such as acute leu-
kemia. Thromboembolism is a common complication in the 
patients suffering from acute leukemia, however preventive 
anticoagulant treatment should be considered according to 
patient’s coagulation – anticoagulation balance.
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